Hala Mirza News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regeneron Reports First Quarter 2021 Financial and Operating Results News provided by Share this article TARRYTOWN, N.Y., May 6, 2021 /PRNewswire/ First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV TM(1) First quarter 2021 Dupixent First quarter 2021 GAAP diluted EPS was $10.09 and non-GAAP diluted EPS (1) Three FDA approvals received: Libtayo ® for first-line advanced non-small cell lung cancer (NSCLC) and advanced basal cell carcinoma (BCC), and Evkeeza TM Positive data reported from Phase 3 trials with REGEN-COV used to treat and prevent COVID-19 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2021 and provided a business update.

United statesHala mirzaLeonards schleiferJustin holkoRoberte landryRegeneron pharmaceuticalsRegeneron pharmaceuticals incNational institutes of healthRegeneron genetics centerNational institutes of protocolDrug administrationData monitoring committeeTeva pharmaceutical industries ltdExchange commissionCorporate communicationsEuropean union